Enliven Therapeutics (ELVN) EBITDA (2019 - 2026)

Enliven Therapeutics has disclosed EBITDA across 8 years of filings, most recently posting -$24.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$24.3 million, up 14.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$99.1 million (down 4.59% YoY), and the FY2025 annual result was -$103.4 million, down 16.05% from the prior year.
• EBITDA came in at -$24.3 million for Q1 2026 at Enliven Therapeutics, up from -$29.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.9 million in Q2 2022 to a low of -$29.6 million in Q4 2025.
• The 5-year median for EBITDA is -$20.0 million (2024), against an average of -$19.5 million.
• Across the five-year window, EBITDA soared 33.37% in 2022 and slumped 99.81% in 2023, its largest moves.
• Enliven Therapeutics' EBITDA stood at -$9.5 million in 2022, then plunged by 99.81% to -$19.1 million in 2023, then fell by 22.46% to -$23.4 million in 2024, then dropped by 26.48% to -$29.6 million in 2025, then rose by 17.63% to -$24.3 million in 2026.
• The last three EBITDA figures came in at -$24.3 million (Q1 2026), -$29.6 million (Q4 2025), and -$19.8 million (Q3 2025), per Business Quant data.